Smart co-delivery of plasmid DNA and doxorubicin using MCM-chitosan-PEG polymerization functionalized with MUC-1 aptamer against breast cancer

dc.contributor.authorEsmaeili, Y.
dc.contributor.authorDabiri, A.
dc.contributor.authorMashayekhi, F.
dc.contributor.authorRahimmanesh, I.
dc.contributor.authorBidram, E.
dc.contributor.authorKarbasi, S.
dc.contributor.authorRafienia M.
dc.date.accessioned2024-05-19T14:33:31Z
dc.date.available2024-05-19T14:33:31Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractThis study introduces an innovative co-delivery approach using the MCM-co-polymerized nanosystem, integrating chitosan and polyethylene glycol, and targeted by the MUC-1 aptamer (MCM@CS@PEG-APT). This system enables simultaneous delivery of the GFP plasmid and doxorubicin (DOX). The synthesis of the nanosystem was thoroughly characterized at each step, including FTIR, XRD, BET, DLS, FE-SEM, and HRTEM analyses. The impact of individual polymers (chitosan and PEG) on payload retardation was compared to the co-polymerized MCM@CS@PEG conjugation. Furthermore, the DOX release mechanism was investigated using various kinetic models. The nanosystem's potential for delivering GFP plasmid and DOX separately and simultaneously was assessed through fluorescence microscopy and flow cytometry. The co-polymerized nanosystem exhibited superior payload entrapment (1:100 ratio of Plasmid:NPs) compared to separately polymer-coated counterparts (1:640 ratio of Plasmid:NPs). Besides, the presence of pH-sensitive chitosan creates a smart nanosystem for efficient DOX and GFP plasmid delivery into tumor cells, along with a Higuchi model pattern for drug release. Toxicity assessments against breast tumor cells also indicated reduced off-target effects compared to pure DOX, introducing it as a promising candidate for targeted cancer therapy. Cellular uptake findings demonstrated the nanosystem's ability to deliver GFP plasmid and DOX separately into MCF-7 cells, with rates of 32% and 98%, respectively. Flow cytometry results confirmed efficient co-delivery, with 42.7% of cells showing the presence of both GFP-plasmid and DOX, while 52.2% exclusively contained DOX. Overall, our study explores the co-delivery potential of the MCM@CS@PEG-APT nanosystem in breast cancer therapy. This system's ability to co-deliver multiple agents preciselyopens new avenues for targeted therapeutic strategies. © 2024 Isfahan university of meeical sciencesen_US
dc.description.sponsorshipIsfahan University of Medical Sciences, IUMS: 1400338, 3400772, 199653; Isfahan University of Medical Sciences, IUMSen_US
dc.description.sponsorshipWe are deeply grateful to Isfahan University of Medical Sciences, Deputy of Research, for their support (Grant No 1400338 & 3400772).en_US
dc.description.sponsorshipWe are deeply grateful to Isfahan University of Medical Sciences, Deputy of Research, for their support (Grant No 199653 & 3400772).en_US
dc.identifier.doi10.1016/j.biopha.2024.116465
dc.identifier.issn0753-3322
dc.identifier.pmid38507955en_US
dc.identifier.scopus2-s2.0-85188706729en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.biopha.2024.116465
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4261
dc.identifier.volume173en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Masson s.r.l.en_US
dc.relation.ispartofBiomedicine and Pharmacotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectBreast Canceren_US
dc.subjectDrug Deliveryen_US
dc.subjectGene Deliveryen_US
dc.subjectSmart Co-Deliveryen_US
dc.subjectTargeted Therapyen_US
dc.titleSmart co-delivery of plasmid DNA and doxorubicin using MCM-chitosan-PEG polymerization functionalized with MUC-1 aptamer against breast canceren_US
dc.typeArticleen_US

Dosyalar